Baxter 70% Dextrose Injection recalled for stainless steel particles
What this means
Baxter is recalling one lot of 70% Dextrose Injection used in hospitals and care facilities because stainless steel particles were found in the solution. If given intravenously, these particles could cause blood clots, block blood vessels, or damage organs. No patient injuries have been reported so far.
- If you work at a healthcare facility, stop using lot Y495066 (expiration 31-Jul-2027) immediately.
- Return all affected units to Baxter according to your facility's process.
- If a home care facility prepared nutrition solutions with this lot, contact your patients to stop using those solutions.
- Call Baxter at 888-229-0001 (Mon–Fri, 7 am–6 pm CT) if you have questions.
- Contact your doctor or call the FDA at 1-800-FDA-0178 if you experienced any problems after receiving this product.
Product photos
The agency's original wording
FOR IMMEDIATE RELEASE – AUG. 25, 2026 – DEERFIELD, Ill., Baxter International Inc. (NYSE:BAX) is voluntarily recalling one lot of 70% Dextrose Injection due to the potential presence of particulate matter identified as stainless steel particles in the solution.
Official notice
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/baxter-issues-voluntary-nationwide-recall-one-lot-70-dextrose-injection-due-potential-presenceMore Baxter recalls
- FDA-PR2026-08-26Baxter Anticoagulant Sodium Citrate Solution recalled for potential fiberglass contamination
- FDA-PR2026-08-25Baxter 0.9% Sodium Chloride Injection recalled for fiberglass particulate matter
- FDA-PR2026-07-24Baxter Cefazolin in Dextrose Injection recalled for cardboard particles in solution
Want us to check the next one for you?
We read every CPSC, FDA, USDA, and NHTSA notice and email you a plain-English Sunday brief covering your household — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.